

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Raskind, Murray A.	POSITION TITLE Professor, Psychiatry and Behavioral Sciences		
eRA COMMONS USER NAME mraskind			
EDUCATION/TRAINING ( <i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i> )			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Brown University, Providence RI	BA	1964	History
Columbia Univ Coll Phys & Surgs, NY, NY	MD	1968	Medicine
Columbia Univ Coll Phys & Surgs, NY, NY	Resident	1968-70	Internal Medicine
University of Washington, Seattle, WA	Resident	1970-73	Psychiatry

**A. Positions and Honors.****Positions and Employment**

1972-1973 Chief Resident, Department of Psychiatry and Behavioral Sciences, University of Washington  
 1973-1976 Instructor, Department of Psychiatry and Behavioral Sciences, University of Washington  
 1975-1979 Assistant Professor, Dept. of Psychiatry and Behavioral Sciences, University of Washington  
 1979-1985 Associate Professor, Dept. of Psychiatry and Behavioral Sciences, University of Washington  
 1985-present Professor and Vice-Chairman, Dept. of Psychiatry and Behavioral Sciences, University of Washington  
 1976-1987 Director, Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA  
 1987-1998 Associate Director, Alzheimer's Disease Research Center (ADRC), University of Washington  
 1996-2009 Director, Mental Health Service, VA Puget Sound Health Care System  
 1997-present Director, Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA  
 1998-present Director, Alzheimer's Disease Research Center (ADRC), University of Washington

**Other Experience and Professional Memberships**

American Psychiatric Association  
 International Society of Psychoneuroendocrinology  
 American College of Neuropsychopharmacology  
 Society for Biological Psychiatry

**Honors**

1985 Outstanding Teacher Award, University of Washington School of Medicine  
 1986-1990 Board of Directors, American Geriatrics Society  
 1986-1992 National Scientific Advisory Council, American Federation of Aging Research  
 1988-1992 Neuroscience, Behavior and Sociology of Aging Review Committee "A", National Institute on Aging, Chairperson 1991-1992  
 1990-2004 Medical and Scientific Advisory Council, Alzheimer's Association  
 2004 Senior Investigator Award, American Association for Geriatric Psychiatry  
 2006 The Carolyn Danz Lifetime Achievement Award  
 2009 Lasting Memory Award, Alzheimer's Association of Western and Central Washington

**B. Selected peer-review publications (in chronological order).** (Selected from 207 publications)

Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. Severe withdrawal symptoms following discontinuation of alprazolam in combat-induced posttraumatic stress disorder. J Clin Psychiatry 51:206-209, 1990.  
 Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Veith RC, Dorsa DM, Murray S, Sikkema C, Galt SA, Wilkinson CW. Enhanced hypothalamic pituitary adrenocortical axis responses to physostigmine in normal aging. J Gerontology 50A:M114-M120, 1995.

- Peskind ER, Wingerson D, Murray S, Pascualy M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA. Enhanced cerebrospinal fluid norepinephrine and behavioral responses to yohimbine in Alzheimer's disease and normal aging. *Arch Gen Psychiatry* 52:774-782, 1995.
- Peskind ER, Wingerson D, Pascualy M, Thal L, Veith RC, Dorsa DM, Bodenheimer S, Raskind MA. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. *Biol Psychiatry* 38:532-538, 1995.
- Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal L, Dobie DJ, Wilkinson CW. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. *Biol Psychiatry* 40:61-68, 1996.
- Tsuang D, Kukull W, Sheppard L, Barnhart RL, Peskind E, Edland SD, Schellenberg G, Raskind M, Larson EB. Impact of sample selection on APOE $\epsilon$ 4 allele frequency: a comparison of two Alzheimer's disease samples. *JAGS* 44:704-707, 1996.
- Tsuang D, Raskind MA, Leverenz J, Peskind ER, Schellenberg GD, Bird TD. The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. *Biol Psychiatry* 41:191-195, 1997.
- Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. *Neuroendocrinology* 65:79-90, 1997.
- Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin DM, Wilkinson CW, Raskind MA. Behavioral and neuroendocrine responses to sodium lactate infusion in PTSD. *Am J Psychiatry* 154:266-268, 1997.
- Planas B, Kolb PE, Raskind MA, Miller MA. Nerve growth factor induces galanin gene expression in the rat basal forebrain: implications for the treatment of cholinergic dysfunction. *J Comp Neurol* 379:563-570, 1997.
- Raskind MA, Sadowsky CH, Sigmund WR, Gracon SL, Beitler PJ, Auster SB. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer's disease. *Arch Neurol* 54:836-840, 1997.
- Planas B, Kolb PE, Raskind MA, Miller MA. Galanin receptors in the hippocampus and entorhinal cortex of aged Fischer 344 male rats. *Neurobiol Aging* 19(5):427-435, 1998.
- Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg G. Tau is a candidate gene for chromosome 17 frontotemporal dementia? *Ann Neurol* 43:815-825, 1998.
- Jensen CF, Peskind ER, Keller TW, McFall ME, Raskind MA. Comparison of sodium lactate-induced panic symptoms between panic disorder and posttraumatic stress disorder. *Depression and Anxiety* 7:122-125, 1998.
- Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr, D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: a relationship to severity of dementia and Apolipoprotein E genotype. *Neurology* 50(1):164-168, 1998.
- Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Grabber JE, Raskind MA, Peskind ER. Effect of chronic high dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. *J Neuroscience* 19:2356-2361, 1999.
- Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB. Clinico-neuropathologic correlation of Alzheimer's disease in a community-based case series. *JAGS* 47:564-569, 1999.
- McFall ME, Fontana A, Raskind MA, Rosenheck R. Analysis of violent behavior in Vietnam combat veteran psychiatric inpatients with posttraumatic stress disorders. *J Traumatic Stress* 12:501-517, 1999.
- McFall ME, Wright PW, Donovan DM, Raskind MA. Multidimensional assessment of anger in Vietnam veterans with posttraumatic stress disorder. *Comp Psychiatry* 40:216-220, 1999.
- Raskind MA, Peskind ER, Holmes C, Goldstein D. Patterns of cerebrospinal fluid catechols support increased cortisol noradrenergic responsiveness in aging and Alzheimer's disease. *Biol Psychiatry* 46:756-765, 1999.
- Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder. *J Clin Psychiatry* 61:129-133, 2000.
- Raskind MA, Peskind ER, Wessel T, Parys W, Yuan M, and the Galantamine USA-1 Study Group. Galantamine in AD – a 6-month randomized, placebo-controlled trial with a 6-month extension. *Neurology* 54:2261-2268, 2000.
- Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. *Neurology* 56:1094-1098, 2001.
- Raskind MA, Peskind ER. Alzheimer's disease and related disorders. *Medical Clinics of North America* 85:803-817, 2001.

- Raskind MA, Barnes RF. Alzheimer's disease: treatment of noncognitive behavioral abnormalities. In: Davis K, Charney D, Coyle J, Nemeroff C (eds), *Psychopharmacology: The Fifth Generation of Progress*. American College of Neuropsychopharmacology, Lippincott Williams and Wilkins, New York, pp 1253-1265, 2002.
- Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall ME, Peskind ER. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. *J Clin Psychiatry* 63:565-568, 2002.
- Raskind MA, Wilkinson CW, Peskind ER. Aging and Alzheimer's disease. In: *Hormones, Brain and Behavior*, Volume 5, Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds), Academic Press:San Diego, CA, pp 637-664, 2002.
- Taylor F, Raskind MA. The alpha-1 adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. *J Clin Psychopharmacol* 22:82-85, 2002.
- Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. *J Geriatr Psychiatry Neurology* 16:165-171, 2003.
- Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson C, Dobie DJ, Hoff D, Rein RJ, Straits-Troster K, Thomas R, McFall ME. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. *Am J Psychiatry* 160:371-373, 2003.
- Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CRV. The cognitive benefits of galantamine are sustained for at least 36 months. A long-term extension trial. *Arch Neurol* 61:252-256, 2004.
- Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. *Neurology* 2005 Jun 28;64(12):2063-8. PMID: 15985573
- Daly CM, Doyle ME, Raskind MA, Peskind ER, Daniels C. Clinical case series: the use of prazosin for combat-related recurrent nightmares in "Operation Iraqi Freedom" combat veterans. *Military Medicine* 170:514-515, 2005.
- Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal V, Vavrek D, Raskind MA. Safety and acceptability of the research lumbar puncture. *Alz Dis Assoc Dis* 19:220-25, 2005.
- Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, Thomas R, Raskind MA. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. *Alz Dis Assoc Dis* 2005 Jan-Mar;19(1):23-8. PMID: 15764868
- Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression. *Brain Res Mol Brain Res*. 2005 Oct 3;139(2):367-71. PMID: 16039007
- Tapp AM, Wood AE, Kilzieh N, Kennedy A, Raskind MA. Antipsychotic polypharmacy: do benefits justify the risks? *Ann Pharmacother* 39:1759-60, 2005.
- Leverenz JB, Fishel MA, Peskind ER, Montine TJ, Nochlin D, Steinbart E, Raskind MA, Schellenberg GD, Bird TD, Tsuang D. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. *Arch Neurol* 2006 Mar;63(3):370-6. PMID: 16533963
- Li G, Cherrier MM, Tsuang DW, Petrie EC, Colasurdo EA, Craft S, Schellenberg GD, Peskind ER, Raskind MA, Wilkinson CW. Salivary cortisol and memory function in human aging. *Neurobiol Aging* 27:1705-14, 2006.
- Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. Age and apolipoprotein E\*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. *Arch Neurol* 2006 Jul;63(7):936-9. PMID: 16831961
- Rasmussen DD, Wilkinson CW, Raskind MA. Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during abstinence. *Alcohol* 38:173-77, 2006.
- Taylor FB, Lowe K, Thompson C, McFall MM, Peskind ER, Kanter ED, Allison N, Williams J, Martin P, Raskind MA. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma PTSD. *Biol Psychiatry* 59:577-81, 2006.
- Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. *J Neurosci* 2006 Jan 11;26(2):467-78. PMID: 16407544
- Tapp AM, Kennedy A, Peskind ER, Raskind MA. Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse. *J Clin Psychiatry* 67:1819-20, 2006.
- Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. *Psychoneuroendocrinology* 32:72-79, 2007.

- Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. *Neurology* 2007 Aug 28;69(9):878-85. PMID: 17724290
- Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. *Neurology* 2007 Aug 14;69(7):631-9. PMID: 17698783
- Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. *Neuropsychopharmacology* 32:284-88, 2007.
- Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbances in combat veterans with posttraumatic stress disorder. *Biol Psychiatry* 61:928-34, 2007.
- Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. *Neuroscience* 2007 Apr 25;146(1):471-80. Epub 2007 Feb 26. PMID: 17324522
- Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma PTSD: a placebo-controlled study. *Biol Psychiatry* 63:629-632, 2008.
- Thompson CE, Taylor FB, McFall ME, Barnes RF, Raskind MA. Non-nightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. *J Trauma Stress* 21(4):417-420, 2008.
- Raskind, MA. Pharmacologic treatment of PTSD. In: *Post-Traumatic Stress Disorder: Basic Science and Clinical Practice*, Shiromani P, Keane T, LeDoux J (eds). Humana Press 2009, pp. 337-361.

### **C. Research Support** **Ongoing Research Support**

P50 AG005136 Raskind (PI and Director)

5/1/05-4/30/10

NIH/NIA

Alzheimer's Disease Research Center

This research center is comprised of large Clinical and Neuropathology Cores that together with a Biostatistics and Data Management Core provides longitudinal clinical assessment and postmortem evaluation of persons with AD, related dementing disorders and control subjects. The Center is a research community and national resource for an array of studies of causes and treatments for Alzheimer's disease. The Center also supports three intrinsic research projects and annual pilot projects.

PT074250 Raskind (PI)

6/1/08-5/31/12

Department of Defense

A Placebo-Controlled Augmentation Trial of Prazosin for Combat Trauma PTSD

Goals: To accelerate the generation of data addressing prazosin efficacy in a large placebo-controlled trial in OIF/OEF returnees to guide evidence-based practice. To accomplish this goal, a 2-arm prazosin vs. placebo augmentation trial in OIF/OEF returnees with PTSD and persistent trauma-related nightmares and sleep disruption will be performed. Subjects will be randomized to prazosin vs. placebo even if on a stable dose of an SSRI or other psychotropic medication(s) provided they still meet symptom inclusion criteria.

VA REAP Raskind (PI)

10/1/05-9/30/10

Department of Veterans Affairs

Research Enhancement Award Program

Adrenergic Mechanisms and Treatment for PTSD and Secondary Drug Abuse (Raskind)

The Research Enhancement Award Program (REAP) combines the expertise of experienced clinical and basic science researchers to create an innovative research and training program addressing adrenergic mechanisms in PTSD and associated substance abuse. The goals are to promote innovative research, foster new research collaborations, and train the next generation of VA investigators to address the etiology and treatment of PTSD and comorbid substance abuse.

Principal Investigator/Program Director (Last, First, Middle):

Prazosin and Combat Trauma PTSD (PACT) Raskind (Co-PI with Elaine Peskind) 10/1/08-9/30/13  
Department of Veterans Affairs  
VA Cooperative Studies Program

The primary goal of this 13 VA site cooperative study is to evaluate the short-term efficacy and long-term effectiveness as well as tolerability of prazosin for trauma nightmares, sleep disturbance, and global clinical status (sense of well-being and ability to function) in veterans with war zone trauma PTSD. We also will assess the effects of prazosin on total PTSD symptoms, depression, quality of life, and alcohol craving.